Local low-dose IL-2 therapy

Willem Den Otter; Lianne Balemans; Jan J. Battermann; Monique R. Bernsen; Jenny A. Cadee; Zygmunt Dobrowolski; Linda A. Everse; Lucja Fiszer-Maliszewska; Richard Gavhumende; Jan Willem De Groot; Kees De Groot; Wim E. Hennink; F. W.Graham Hill; Ina Jurgenliemp-Schulz; Wim R. Klein; Jan Willem Koten; Riks A. Maas; Peter Steerenberg; Rachel Stewart; Marek Zembala

Local low-dose IL-2 therapy

Willem Den Otter^*, Lianne Balemans, Jan J. Battermann, Monique R. Bernsen, Jenny A. Cadee, Zygmunt Dobrowolski, Linda A. Everse, Lucja Fiszer-Maliszewska, Richard Gavhumende, Jan Willem De Groot, Kees De Groot, Wim E. Hennink, F. W.Graham Hill, Ina Jurgenliemp-Schulz, Wim R. Klein, Jan Willem Koten, Riks A. Maas, Peter Steerenberg, Rachel Stewart, Marek Zembala

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

23 Citations (Scopus)

Abstract

Interleukin-2 (IL-2) is a powerful drug for treating cancer. However, it is only powerful if it is properly applied. That is, IL-2 should be applied at the tumor site, because at the transition of normal and malignant tissue are the tumor infiltrating cells. These should be activated by IL-2. Local application implies that IL-2 can be used in relatively low doses. It is becoming clear that even a single injection of IL-2 can cure cancer. IL-2 can also enhance the therapeutic effects of irradiation and Cisplatin. Locally applied IL-2 therapy is virtually non-toxic.

Original language	English
Pages (from-to)	1280-1286
Number of pages	7
Journal	Hepato-Gastroenterology
Volume	46
Issue number	SUPPL. 1
Publication status	Published - 1999
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Den Otter, W., Balemans, L., Battermann, J. J., Bernsen, M. R., Cadee, J. A., Dobrowolski, Z., Everse, L. A., Fiszer-Maliszewska, L., Gavhumende, R., De Groot, J. W., De Groot, K., Hennink, W. E., Hill, F. W. G., Jurgenliemp-Schulz, I., Klein, W. R., Koten, J. W., Maas, R. A., Steerenberg, P., Stewart, R., & Zembala, M. (1999). Local low-dose IL-2 therapy. Hepato-Gastroenterology, 46(SUPPL. 1), 1280-1286.

@article{22637713b2e14a91a0baa7e62ae9ad1b,

title = "Local low-dose IL-2 therapy",

abstract = "Interleukin-2 (IL-2) is a powerful drug for treating cancer. However, it is only powerful if it is properly applied. That is, IL-2 should be applied at the tumor site, because at the transition of normal and malignant tissue are the tumor infiltrating cells. These should be activated by IL-2. Local application implies that IL-2 can be used in relatively low doses. It is becoming clear that even a single injection of IL-2 can cure cancer. IL-2 can also enhance the therapeutic effects of irradiation and Cisplatin. Locally applied IL-2 therapy is virtually non-toxic.",

author = "\{Den Otter\}, Willem and Lianne Balemans and Battermann, \{Jan J.\} and Bernsen, \{Monique R.\} and Cadee, \{Jenny A.\} and Zygmunt Dobrowolski and Everse, \{Linda A.\} and Lucja Fiszer-Maliszewska and Richard Gavhumende and \{De Groot\}, \{Jan Willem\} and \{De Groot\}, Kees and Hennink, \{Wim E.\} and Hill, \{F. W.Graham\} and Ina Jurgenliemp-Schulz and Klein, \{Wim R.\} and Koten, \{Jan Willem\} and Maas, \{Riks A.\} and Peter Steerenberg and Rachel Stewart and Marek Zembala",

year = "1999",

language = "English",

volume = "46",

pages = "1280--1286",

journal = "Hepato-Gastroenterology",

issn = "0172-6390",

publisher = "H.G.E. Update Medical Publishing Ltd.",

number = "SUPPL. 1",

}

Den Otter, W, Balemans, L, Battermann, JJ, Bernsen, MR, Cadee, JA, Dobrowolski, Z, Everse, LA, Fiszer-Maliszewska, L, Gavhumende, R, De Groot, JW, De Groot, K, Hennink, WE, Hill, FWG, Jurgenliemp-Schulz, I, Klein, WR, Koten, JW, Maas, RA, Steerenberg, P, Stewart, R & Zembala, M 1999, 'Local low-dose IL-2 therapy', Hepato-Gastroenterology, vol. 46, no. SUPPL. 1, pp. 1280-1286.

TY - JOUR

T1 - Local low-dose IL-2 therapy

AU - Den Otter, Willem

AU - Balemans, Lianne

AU - Battermann, Jan J.

AU - Bernsen, Monique R.

AU - Cadee, Jenny A.

AU - Dobrowolski, Zygmunt

AU - Everse, Linda A.

AU - Fiszer-Maliszewska, Lucja

AU - Gavhumende, Richard

AU - De Groot, Jan Willem

AU - De Groot, Kees

AU - Hennink, Wim E.

AU - Hill, F. W.Graham

AU - Jurgenliemp-Schulz, Ina

AU - Klein, Wim R.

AU - Koten, Jan Willem

AU - Maas, Riks A.

AU - Steerenberg, Peter

AU - Stewart, Rachel

AU - Zembala, Marek

PY - 1999

Y1 - 1999

N2 - Interleukin-2 (IL-2) is a powerful drug for treating cancer. However, it is only powerful if it is properly applied. That is, IL-2 should be applied at the tumor site, because at the transition of normal and malignant tissue are the tumor infiltrating cells. These should be activated by IL-2. Local application implies that IL-2 can be used in relatively low doses. It is becoming clear that even a single injection of IL-2 can cure cancer. IL-2 can also enhance the therapeutic effects of irradiation and Cisplatin. Locally applied IL-2 therapy is virtually non-toxic.

AB - Interleukin-2 (IL-2) is a powerful drug for treating cancer. However, it is only powerful if it is properly applied. That is, IL-2 should be applied at the tumor site, because at the transition of normal and malignant tissue are the tumor infiltrating cells. These should be activated by IL-2. Local application implies that IL-2 can be used in relatively low doses. It is becoming clear that even a single injection of IL-2 can cure cancer. IL-2 can also enhance the therapeutic effects of irradiation and Cisplatin. Locally applied IL-2 therapy is virtually non-toxic.

UR - https://www.scopus.com/pages/publications/0033049083

M3 - Article

C2 - 10429975

AN - SCOPUS:0033049083

SN - 0172-6390

VL - 46

SP - 1280

EP - 1286

JO - Hepato-Gastroenterology

JF - Hepato-Gastroenterology

IS - SUPPL. 1

ER -

Local low-dose IL-2 therapy

Abstract

UN SDGs

Other files and links

Fingerprint

Cite this